Congress Asset Management Co. Has $80.62 Million Stock Holdings in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Congress Asset Management Co. increased its stake in Prestige Consumer Healthcare Inc. by 1.8% in Q2, holding approximately $80.62 million in stock as of its latest SEC filing.
• The company's recent earnings report showed $0.95 EPS, missing estimates, alongside a revenue decline of 6.6% year over year.
• Analysts have mixed ratings on the stock, with the average target price set at $94.80, indicating a potential for growth despite some downgrades.

Congress Asset Management Co. increased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,009,595 shares of the company's stock after acquiring an additional 18,015 shares during the period. Congress Asset Management Co. owned about 2.04% of Prestige Consumer Healthcare worth $80,616,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in PBH. Cetera Investment Advisers acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $413,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Prestige Consumer Healthcare by 24.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 118,113 shares of the company's stock valued at $9,223,000 after purchasing an additional 23,334 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at approximately $7,778,000. Wealth Enhancement Advisory Services LLC lifted its stake in Prestige Consumer Healthcare by 14.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company's stock valued at $649,000 after purchasing an additional 1,030 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Prestige Consumer Healthcare by 11,580.3% in the 1st quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock valued at $13,887,000 after purchasing an additional 160,155 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $62.78 on Friday. The company has a fifty day moving average price of $68.09 and a 200-day moving average price of $77.83. The company has a market capitalization of $3.09 billion, a P/E ratio of 14.74, a PEG ratio of 2.00 and a beta of 0.46. Prestige Consumer Healthcare Inc. has a 52-week low of $61.93 and a 52-week high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. Prestige Consumer Healthcare's revenue was down 6.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PBH shares. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Sidoti raised shares of Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price objective for the company in a research note on Wednesday. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Zacks Research downgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research note on Thursday, September 4th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $94.80.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.